What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “fixed-dose oral tablet of sildenafil + cabergoline (low-dose 25/0.25 mg; high-dose 50/0.5 mg). Single oral dose.”In the company’s words, NCT07732387 on ClinicalTrials.gov
- Tested for
- Erectile Dysfunctions
- Main trialPhase 1
- “This is a Phase 1, open-label, single-ascending-dose study evaluating the safety, tolerability, and pharmacokinetics (PK) of Viaca - a fixed-dose oral combination of sildenafil (a PDE5 inhibitor) and cabergoline (a dopamine D2 agonist) - versus sildenafil monotherapy and cabergoline monotherapy in healthy adult male volunteers. Approximately 30 participants are enrolled across 5 sequential cohorts (6 each). Each participant receives a single oral dose. The combination targets erectile dysfunction through both vascular and neuroendocrine pathways, aiming for efficacy at lower component doses.”In the company’s words, NCT07732387 on ClinicalTrials.gov
Other drugs for Erectile Dysfunctions
- W2505GL Pharm Tech Corporation · Phase 3
- HIP2602 + HPP2602-2Hanmi · Phase 3
- DTT106EMS · Phase 3
- PrimePro/ PrimeMSKThomas Advanced Medical LLC · Phase 1/2
- HezkueAspargo Labs, Inc · Phase 2
- Hezkue TurboAspargo Labs, Inc · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | 19 Sep 2026 | A Study to Assess the Safety, Tolerability and Pharmacokinetics of Viaca (Sildenafil + Cabergoline) Compared With Sildenafil and Cabergoline |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026